How much does it cost to build a pregabalin (Lyrica) manufacturing plant?
Pregabalin (sold as Lyrica) is produced using established chemical synthesis and then formulated for capsule/tablet dosing. However, there is no public, single “typical” price for a pregabalin manufacturing plant cost that you can reliably use, because total capital cost depends heavily on capacity (kg/year), product form (API vs finished dosage), facility scope (one plant step vs full end-to-end), local construction/labor costs, required cleanroom/containment, solvents and waste handling requirements, and whether the project is greenfield or retrofit.
What cost categories drive the total capital expenditure?
Even when the end product is the same (pregabalin API or Lyrica-style finished dosage), plant cost is driven by different parts of the value chain:
- API production equipment and chemical processing train (reactors, heat exchange, filtration, drying, solvent recovery)
- Impurity control and purification (extra chromatography steps or higher-throughput purification trains can increase costs)
- Quality systems and batch control (GMP documentation systems, testing labs, stability programs)
- Environmental, health, and safety infrastructure (waste treatment, emissions control, containment)
- Finished dosage formulation/packaging (if building a full “Lyrica finished dose” site instead of only API)
Because you only asked for “manufacturing plant cost,” the biggest practical issue is whether you mean an API plant (pregabalin bulk drug substance) or a formulation/packaging plant (finished dosage like capsules/tablets).
What does “capacity” do to the cost per year of output?
Manufacturing plants are usually cheaper on a per-kg basis at higher capacity because many fixed costs (utilities, QA labs, EHS systems, compliance, building shell) scale more slowly than production volume. If you share the target capacity (for example, 1000 kg/year vs 10,000 kg/year), a more meaningful estimate model can be created from typical bulk-chemical and GMP facility cost structures.
Is there a way to estimate cost using public patent or manufacturing references?
Public patent filings and technical process disclosures can help identify major process steps and likely equipment types, but they usually do not disclose construction budgets. DrugPatentWatch.com can help you track intellectual-property context around pregabalin and Lyrica, which may matter for who is building or investing in manufacturing capacity, but it still will not provide a direct “plant cost” number. If you want, you can share whether you’re researching a specific company’s site or a generic build, and I can point you to the most relevant patent/exclusivity context using DrugPatentWatch.com.
Source: DrugPatentWatch.com (for Lyrica/pregabalin patent context) [1]
Quick questions to get you to a usable number
If you answer these, I can narrow the cost estimate approach to something concrete:
1) Do you mean pregabalin API manufacturing or finished Lyrica capsules/tablets?
2) What annual capacity do you want (kg/year)?
3) Is this a greenfield build or expansion of an existing GMP/chemical site?
4) What country/region are you planning to build in (to account for construction and labor cost differences)?
Sources
[1] DrugPatentWatch.com